Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer-related death worldwide. The first-line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have shown limited response rates and survival benefits with sorafenib. Although sorafenib is an inhibitor of multiple kinases, including serine/threonine-protein kinase cRaf, serine/threonine-protein kinase B-Raf, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor b, HCC cells are able to escape from sorafenib treatment using other pathways that the drug insufficiently inhibits. The aim of this study was to identify and target survival and proliferation pathways that enable HCC to escape the antitumor activity of sorafenib. We found that insulin-like growth factor 1 receptor (IGF1R) remains activated in HCC cells treated with sorafenib. Knockdown of IGF1R sensitizes HCC cells to sorafenib treatment and decreases protein kinase B (AKT) activation. Overexpression of constitutively activated AKT reverses the effect of knockdown of IGF1R in sensitizing HCC cells to treatment with sorafenib. Further, we found that ceritinib, a drug approved by the U.S. Food and Drug Administration for treatment of non-small cell lung cancer, effectively inhibits the IGF1R/AKT pathway and enhances the inhibitory efficacy of sorafenib in human HCC cell growth and survival in vitro, in a xenograft mouse model and in the c-Met/b-catenin-driven HCC mouse model. Conclusion: Our study provides a biochemical basis for evaluation of a new combination treatment that includes IGF1R inhibitors, such as ceritinib and sorafenib, in patients with HCC. (Hepatology Communications 2018;2:732-746) H epatocellular carcinoma (HCC) is the primary malignancy of the liver and is now the second leading cause of cancer deaths worldwide.
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(1) Low rates of early diagnosis coupled with high mortality rates make it critical to develop new treatment approaches to HCC. (2) The multikinase inhibitor sorafenib is the first-line treatment for advanced HCC, but the clinical impact of sorafenib is modest (2%-3.3% objective partial response rate, 54%-71% disease stabilization rate, and a nearly 3-month survival advantage over placebo). (3) Sorafenib suppresses tumor proliferation and angiogenesis by inhibiting multiple serine/threonine and receptor tyrosine kinases, including serine/threonine-protein kinase Raf-1 (or c-Raf), wild-type and mutant B-Raf, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor b, tyrosine-protein kinase Kit (c-KIT), FMSlike tyrosine kinase 3 (FLT-3), and proto-oncogene tyrosine-protein kinase receptor Ret (RET). (4) However, other signaling pathways that sorafenib fails to inhibit can contribute to cell growth and survival in sorafenib-acquired resistant cells, such as the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. (5) Therefore, combination drug treatment to inhibit the remaining active cell survival and growth pathways appears to be a promising approach to improve sorafenib efficacy. (6, 7) Insulin-like growth factor 1 receptor (IGF1R) is a receptor for IGF. IGF1R is activated through ligandinduced phosphorylation and subsequently phosphorylates and activates both the PI3K/AKT and Ras/mitogen-activated protein kinase pathways. (8) Activation of IGF1R is crucial for malignant transformation and the survival of malignant cells. (8) (9) (10) For example, aberrant expression and activation of IGF1R contributes to increased survival of pancreatic cancer cells, (11) and knockdown of IGF1R led to inhibition of proliferation, migration, and invasiveness of prostate cancer cells. (12) Overexpression of IGF1R was detected in 33% of human HCCs, and increased activation of IGF1R was observed in 52% of HCC tumors. (13) Abrogation of IGF1R activation significantly but modestly decreases HCC cell viability and proliferation. (14) Although several IGF1R inhibitors have been tested in clinical trials, (9, 15, 16) none have been approved by the U.S. Food and Drug Administration (FDA). Intriguingly, ceritinib (Zykadia), a potent anaplastic lymphoma kinase (ALK) inhibitor that is FDA approved for treatment of non-small cell lung cancer, (17) has been reported to effectively inhibit IGF1R. (18) In this study, we found that IGF1R remains activated in HCC cells after treatment with sorafenib. Moreover, knockdown of IGF1R sensitizes HCC cells to sorafenib by decreasing AKT activation. Overexpression of constitutively activated AKT reverses the effect of IGF1R knockdown in sensitizing HCC cells to sorafenib treatment. Furthermore, we found that ceritinib decreases phosphorylation of IGF1R and AKT and enhances the efficacy of inhibition by sorafenib in human HCC cell growth and survival in in vitro and in vivo models. Our study provides evidence that the combination of ceritinib and sorafenib has therapeutic potential for HCC and elucidates its possible mechanisms.
Materials and Methods

CELLS AND REAGENTS
Huh7 cells were purchased from the Japanese Collection of Research Bioresources Cell Bank. Hep3B, HepG2, and 293T cells were purchased from the American Type Culture Collection. All cells were cultured with Dulbecco's modified Eagle's medium (high glucose; Thermo Scientific, Waltham, MA), supplemented with 10% fetal bovine serum (Tissue Culture Biologicals) and penicillin and streptomycin (SigmaAldrich, St. Louis, MO) in a humidified atmosphere of 5% CO 2 at 378C. Cells were plated in 12 or 6-well plates at 30%-40% density for 24 hours prior to treatment. Ceritinib was purchased from LC Laboratories (Cat#2086; Woburn, MA), and sorafenib was purchased from MedKoo Bioscience (Cat#100770a; Morrisville, NC).
MICE
All animals received humane care according to the Guide for the Care and Use of Laboratory Animals (http://oacu.od.nih.gov/ac_cbt/guide3.htm). The procedures for all animal experiments were approved by the Institutional Animal Care and Use Committee of Loyola University Chicago. The mice were housed in micro-isolator cages in a room illuminated from 7:00 AM to 7:00 PM (12-hour:12-hour light-dark cycle) and allowed access to water and chow ad libitum. C57BL/6 mice were obtained from the Jackson Laboratory, and severe combined immunodeficiency mice (SCID-bg) were purchased from Charles River.
CELL PROLIFERATION/VIABILITY ANALYSIS BY ALAMARBLUE ASSAY
Hep3B, Huh7, and HepG2 cells were seeded into 96-well plates (5 3 10 3 cells/well). After 24 hours, cells were treated with ceritinib (0.5-1.5 lM), sorafenib (1.25-5.0 lM), or both. At different time points, culture media was removed and alamarBlue (BUF012A; Bio-Rad, Hercules, CA) solution (1:10 dilution in phosphate-buffered saline) was added to the cells. After a 2-hour incubation at 378C, fluorescence values were measured with a fluorescent plate reader at 530-560 nm excitation/590 nm emission.
LENTIVIRAL PARTICLE PREPARATION
For IGF1R knockdown experiments, Hep3B cells were infected with lentiviral plasmid (p)LKO.1 particles that contained IGF1R or scrambled short hairpin (sh) RNA and selected with 2 lg/mL puromycin for 5 days. Lentiviral pLKO.1 plasmids for shIGF1R (Table 1) or scrambled shRNA (SHC002; SigmaAldrich) were packaged with the cytomegalovirus plasmid (pCMV)-dr8.2 (Addgene) and pCMV-VSVG (Addgene) in 293T cells to produce lentiviral particles as described. (19, 20) For overexpression of constitutively active AKT experiments, Hep3B cells were infected with lentiviral particles packaged with FG12-cmv-green fluorescent protein (gfp)-akt (constitutively active AKT) or FG12-cmv-gfp, pCMVD8.71, and pMD.G in 293T cells. Six days after infection, GFP-positive cells expressing constitutively active AKT were sorted by flow cytometry (FACSAria Cell Sorter).
COLONY FORMATION ASSAY
Hep3B cells were seeded into 12-well plates (6 3 10 3 cells/well) for 24 hours before treatment as described. (21) After 48 hours of treatment with dimethyl sulfoxide, 1.25 lM sorafenib, 0.5 lM ceritinib, or a combination of both drugs, media was changed and the cells were cultured for 14 days. Cells were fixed in a mixture of 6.0% glutaraldehyde and stained with 0.5% crystal violet. Colonies were scored in at least four fields (magnification 340) and reported as means 6 SD.
XENOGRAFT MODEL
SCID-bg mice were shaved following anesthesia using isoflurane, and 5 3 10 6 Hep3B cells in 100 lL of serum-free media was injected into the left or right flanks of the mice. Two weeks postinjection, mice were treated with vehicle (30% captisol), ceritinib (25 mg/kg), sorafenib (25 mg/kg), or a combination of sorafenib (25 mg/kg) and ceritinib (25 mg/kg) by oral gavage daily. Tumor volumes were measured daily using a caliper until the day of sacrifice. Tumor volume was calculated using the ellipsoidal formula as follows: tumor volume (mm
, where L is the greatest longitudinal distance of the tumor and W is the greatest transverse distance of the tumor. Tumors were harvested prior to volume growth beyond the humane threshold of 1,500 mm 3 .
MET/CAT-DRIVEN HCC MODEL
For the c-met (MET)/constitutively active b-catenin (CAT)-driven HCC model, (19, (22) (23) (24) 55 lg of total plasmids, encoding the sleeping beauty transposase (HSB2) and transposons with oncogenes MET/CAT and gaussia luciferase (Gluc) (22.5 lg pT3-EF1a-c-MET [human], 22.5 lg pT3-EF1a-DN90-b-catenin [human], 5 lg pT3-Gluc1, and 5 lg HSB2) were injected hydrodynamically into age-and sex-matched mice. Six weeks after MET/CAT injection, mice were treated with vehicle (30% captisol), ceritinib (25 mg/ kg), sorafenib (25 mg/kg), or a combination of ceritinib and sorafenib by oral gavage daily for 4 weeks prior to being sacrificed. All mice were maintained on the standard diet. Liver and body weights of each mouse were measured and recorded.
WESTERN BLOTTING
Western blotting was performed as described. (19, 25) Primary antibodies, including those for IGF1R, phosphorylated IGF1R, caspase-3, active caspase-3, poly(adenosine diphosphate ribose) polymerase, phosphorylated (p-)AKT (ser473), AKT, p-extracellular signal-regulated kinase (ERK), and ERK, were purchased from Cell Signaling Technology (Danvers, MA). Glyceraldehyde 3-phosphate dehydrogenase and b-actin antibodies were purchased from Sigma. More detailed information can be found in Table 2 .
Ki67 IMMUNOHISTOCHEMICAL STAINING
Immunohistochemistry was performed as described. (25) Detailed antibody information can be found in Table 2 . Cells with positive staining were scored in at least five fields (magnification 3400) and reported as means 6 SD. Three mice were used in each group.
TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE-MEDIATED DEOXYURIDINE TRIPHOSPHATE NICK-END LABELING
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining was performed as described (26) using a kit purchased from Millipore (Cat#S7101). The TUNELpositive cell numbers were scored in at least five fields (magnification 3400) per mouse and are reported as means 6 SD. Three mice were used in each group.
STATISTICAL ANALYSIS
Statistical analysis was carried out using GraphPad Prism V software. Data are presented as means 6 SD (shown in the figures where applicable). Statistical significance was calculated with the Student t test, and P < 0.05 was considered significant.
Results
KNOCKDOWN OF IGF1R ENHANCES THE INHIBITION EFFICACY OF SORAFENIB ON HCC CELL GROWTH BY INHIBITING AKT
Although sorafenib inhibits multiple kinase activities to suppress tumor angiogenesis and proliferation, other signaling pathways, such as PI3K/AKT, which sorafenib does not inhibit at low or even higher doses, contribute to cell growth and survival in sorafenibacquired resistant cells. (5) The IGF1R signal pathway has been reported to be enriched in sorafenib-acquired resistant tumor cells. (27) Therefore, we examined whether IGF1R remains active after sorafenib treatment in HCC cells. We found that sorafenib failed to inhibit IGF1R phosphorylation at Tyr1131, which is required for activation of IGF1R's kinase, (28) in three HCC cell lines (Fig. 1A) . Phosphorylation of AKT was also not decreased by sorafenib ( Fig. 1A ; Supporting Fig. S1B ). However, phosphorylation of ERK, a downstream target of RAF/mitogen-activated protein kinase/ERK kinase (MEK), (29) was decreased after sorafenib treatment, indicating sorafenib had activity against ERK in all three HCC cell lines (Fig. 1A) . To determine whether IGF1R activity remains contributory to HCC cell growth and survival after sorafenib treatment, we used lentiviral shRNAs to knock down IGF1R expression in Hep3B cells. We found that knockdown of IGF1R enhanced the inhibitory efficacy of sorafenib on Hep3B cell growth (Fig. 1B,C) . Further, knockdown of IGF1R decreased the phosphorylation of AKT but not ERK in Hep3B cells (Fig. 1B) . To determine whether knockdown of IGF1R enhances the inhibitory efficacy of sorafenib on HCC cell growth by inhibiting AKT activity, we overexpressed constitutively active AKT in IGF1R knockdown cells (Fig. 1D) . We found that overexpression of constitutively active AKT abrogated the ability of IGF1R knockdown to sensitize HCC cells to sorafenib (Fig.  1E) . In general, these data indicate that knockdown of IGF1R sensitizes HCC cells to sorafenib treatment by inhibiting AKT activity.
CERITINIB ENHANCES THE EFFICACY OF SORAFENIB IN INHIBITING HCC CELL GROWTH AND SURVIVAL
To determine whether the use of a combination treatment using IGF1R inhibitors and sorafenib is a viable clinical translational strategy to treat HCC, we examined whether ceritinib, an FDA-approved dual ALK and IGF1R inhibitor for the treatment of nonsmall cell lung cancer, (17, 18) further sensitizes HCC cells to sorafenib treatment. To do so, we first examined the effect of ceritinib on HCC cell growth, which has not been reported. We found that ceritinib effectively inhibited IGF1R activity, which was marked by the phosphorylation of IGF1R and AKT, in HCC cells. Interestingly, ERK phosphorylation was not affected by ceritinib (Fig. 2A) . As ceritinib is also an ALK inhibitor, we examined whether ceritinib inhibits ALK activity in a number of HCC cell lines, including Hep3B, Huh7, and HepG2. We found that ALK expression was too low to be detected in these cell lines ( Fig. 2A) , suggesting that ALK does not play an important role in the growth of these HCC cells. We also found that ceritinib inhibited the growth of HCC cells (Fig. 2B) , which phenocopies the effect of knockdown of IGF1R in HCC cells (Fig. 2C) . In addition, overexpression of constitutively active AKT abrogated the inhibitory effect on HCC cell growth by either ceritinib or knockdown of IGF1R (Fig. 2D,E) . These results suggest that ceritinib suppresses HCC cell growth by inhibiting the IGF1R/AKT pathway.
We next examined whether ceritinib enhances the inhibitory efficacy of sorafenib on HCC cell growth and survival. Indeed, ceritinib enhanced the efficacy of sorafenib in inhibiting HCC cell growth in a doseand time-dependent manner (Fig. 3A,B) . Further, we found that ceritinib increased sorafenib-induced cellular apoptosis, marked by cleavage of caspase-3 and poly(adenosine diphosphate ribose) polymerase (Fig. 3C) . Collectively, our data indicate that ceritinib enhances the inhibitory efficacy of sorafenib on HCC cell growth and survival.
CERITINIB ENHANCES THE EFFICACY OF SORAFENIB IN INHIBITING HCC CELL GROWTH AND SURVIVAL BY INHIBITING THE IGF1R/AKT PATHWAY
To determine whether ceritinib enhances the efficacy of sorafenib in inhibiting HCC cell growth and survival by inhibiting the IGF1R/AKT pathway, we first examined the levels of phosphorylated IGF1R and AKT by western blotting. We found decreased phosphorylation of IGF1R in HCC cells treated with a combination of ceritinib and sorafenib compared to such cells treated with sorafenib alone (Fig. 4A) . The level of phosphorylated AKT was also decreased in HCC cells treated with a combination of ceritinib and sorafenib compared to such cells treated with sorafenib alone (Fig. 4A) , even when phosphorylation of AKT was increased by sorafenib treatment in HepG2 and Huh7 cells (Fig. 4A) ; this is consistent with results reported by other groups. (5) Notably, the level of phosphorylated ERK was not further decreased by ceritinib in HCC cells treated with a combination of ceritinib and sorafenib compared to such cells treated with sorafenib alone (Fig. 4A) . Importantly, overexpression of constitutively active AKT rescued the ability of ceritinib to sensitize HCC cells to sorafenib treatment (Fig.  4B,C) , suggesting that ceritinib enhances the efficacy of sorafenib in inhibiting HCC cell growth and survival by inhibiting the IGF1R/AKT pathway. 
CERITINIB ENHANCES THE EFFICACY OF SORAFENIB IN INHIBITING HCC TUMOR GROWTH IN VIVO
To further investigate the efficacy of ceritinib in sensitizing HCC cells to sorafenib treatment in vivo, we first examined the effect of the combination of ceritinib and sorafenib in a xenograft model. We found that treatment with either ceritinib or sorafenib alone was able to inhibit tumor growth while combination treatment using ceritinib and sorafenib had the best overall effectiveness (Fig. 5A-C) . Importantly, mouse weight was not significantly affected by the combination treatment, suggesting minimal toxicity for the combination treatment regimen (Fig. 5D) . We further confirmed that ceritinib treatment inhibited IGF1R and AKT activities in xenografted tumors (Fig. 5E) . Additionally, we found that combination treatment with ceritinib and sorafenib further decreased tumor cell proliferation (Fig. 5F ) and increased tumor cell apoptosis ( Fig. 5G; Supporting Fig. S2 ) compared to sorafenib or ceritinib treatment alone. Overall, our xenograft model results demonstrate that ceritinib enhances the efficacy of sorafenib in inhibiting human HCC tumor growth.
To further test the efficacy of ceritinib in sensitizing HCC cells to sorafenib treatment in a mouse model with intact immune responses, we used the MET/ CAT-driven HCC model. Co-activation of MET and b-catenin often occurs in HCC. (22) Codelivery of both MET and CAT (DN90-b-catenin, exon 3 deleted), but neither MET nor CAT alone, into mouse livers using the sleeping beauty transposon system efficiently induces HCC within several weeks. (22) (23) (24) Therefore, this model (referred to here as MET/CAT) is useful for studying the functions of genes in hepatocarcinogenesis because of its clinical relevance and efficiency of HCC induction. We found that both IGF1R and AKT are activated in MET/CAT-induced HCCs (Fig. 6A) . We injected C57B6/J mice with MET/ CAT to induce HCC and then treated them with vehicle, ceritinib, sorafenib, or a combination of both drugs for 4 weeks. Consistent with the results from our xenograft model, either ceritinib or sorafenib when used alone was able to inhibit HCC development, but the combination treatment had the best efficacy in tumor inhibition (Fig. 6B,C; Supporting Fig. S3 ).
FIG. 7.
Schematic model. Sorafenib inhibits its downstream targets RAF, VEGF, and PDGF, resulting in inhibition of MEK/ERK activity, which leads to inhibition of HCC cell proliferation and survival. However, HCC cells are able to escape from sorafenib's effects using other resistance pathways that sorafenib insufficiently inhibits. IGF1R/AKT is such a sorafenib-resistant pathway. IGF1R remains activated after sorafenib treatment in HCC cells and its activity leads to AKT activation, which is critical for HCC cell proliferation and survival. Ceritinib is a potent IGF1R inhibitor. Ceritinib effectively inhibits the IGF1R/AKT pathway but fails to suppress ERK activity. Therefore, ceritinib alone has a modest effect on HCC cell proliferation and survival. The combination of sorafenib and ceritinib effectively inhibits both the MEK/ERK and IGF1R/AKT pathways, which results in more effective inhibition of HCC cell growth compared to either sorafenib or ceritinib used alone. Abbreviations: MEK, mitogen-activated protein kinase/ ERK kinase; PDGF, platelet-derived growth factor.
Mouse weights also were not significantly changed by the combination treatment, suggesting tolerable toxicity of the combination treatment in mice with intact immune responses (Fig. 6D) . Phosphorylation of both IGF1R and AKT was also inhibited by ceritinib treatment in MET/CAT-induced tumors (Fig. 6E) . Furthermore, combination treatment with ceritinib and sorafenib decreased tumor cell proliferation (Fig. 6F ) and increased tumor cell apoptosis (Fig. 6G) compared to ceritinib or sorafenib monotherapy in this model. Overall, our data demonstrate that ceritinib enhances the efficacy of sorafenib in inhibiting HCC tumor growth in preclinical mouse models with intact immune responses.
Discussion
HCC is a common and fatal malignancy of the liver and is the second leading cause of cancer-related mortality in the world. (1, 30) Sorafenib, the first-line oral therapeutic agent for advanced HCC increases patient survival by less than 3 months. Regorafenib was recently approved by the FDA for treatment of patients with HCC who do not or no longer respond to sorafenib, but it only increases survival by about 3 months. (31) Nivolumab, a programmed cell death protein 1 inhibitor, also was approved to treat sorafenibtreatment failures, but the overall response rate was only 14.3% (22/154) (http://www.opdivohcp.com/ advanced-hcc/efficacy/clinical-trial-results). Therefore, there is still an urgent need to develop new and more effective therapeutic agents and strategies to treat HCC. In this study, we demonstrate that inhibition of IGF1R efficiently increases sensitivity of HCC cells to sorafenib treatment in in vitro and in vivo models. The findings of the current study provide a basis to investigate a new combination of sorafenib with an IGF1R inhibitor, such as ceritinib, for treatment of HCC.
IGFIR overactivation is one of the hallmarks of HCC and can be mediated by increased levels of IGFIR protein and/or an excess of IGF ligands. (32) Healthy mature hepatocytes do not express IGFIR. (16) In HCC samples, up-regulation of IGFIR is one of the most common alterations, occurring in 30% of patients. (33) Activation of IGFIR signaling in HCC was significantly associated with AKT and mammalian target of rapamycin signaling. (16) In vitro studies showed that abrogation of IGF1R activation and downstream signaling by the monoclonal antibody A12 significantly decreased cell viability and proliferation. (14) In vivo, A12 delayed tumor growth and prolonged survival, reducing proliferation rates and inducing apoptosis. (14) Although several IGF1R inhibitors or blocking antibodies have been tested in preclinical models or clinical trials for patients with HCC, (9, (14) (15) (16) none has been approved by the FDA, possibly because inhibition of IGF1R alone may not be sufficient to effectively inhibit HCC cell growth and survival. Our data support this hypothesis as inhibition of IGF1R by shRNA or ceritinib has only a modest suppression on HCC proliferation and survival ( Figs. 1 and 2 ). However, we show for the first time that the combination of sorafenib and the IGF1R inhibitor ceritinib is more effective against HCC in in vitro and in vivo models compared to sorafenib or inhibition of IGF1R alone. The addition of an IGF1R inhibitor is advantageous because sorafenib is insufficient to inhibit IGF1R and downstream AKT activation in HCC cells and IGF1R is critical for AKT activation, which promotes HCC cell proliferation and survival. (34) Combination treatment using sorafenib and IGF1R inhibitors not only suppresses plateletderived growth factor receptor, VEGFR, and RAF phosphorylation but also inhibits the IGF1R/AKT axis, resulting in a more efficacious anti-HCC effect (Fig. 7) .
Ceritinib is well known as an adenosine triphosphate-competitive tyrosine kinase inhibitor of ALK. Intriguingly, the expression of both ALK ( Fig.  2A ) and p-ALK in the HCC cell lines (Hep3B, Huh7, and HepG2) is very low (data not shown). Therefore, it is unlikely that ceritinib sensitizes these HCC cells to sorafenib by inhibiting ALK. Two recent studies indicate that ALK is overexpressed in 13%-44% human HCC and that this overexpression is correlated with poor prognosis. (35, 36) ALK can be activated by different ligands (e.g., growth factors pleiotrophin or midkine) and various pathways. (37) Therefore, it is likely that ceritinib inhibits ALK activity in some patients with HCC. We found that overexpression of ALK decreases the sensitivity of HCC cells to sorafenib (data not shown), suggesting inhibition of ALK might sensitize HCC cells to sorafenib. Therefore, combination therapy consisting of ceritinib plus sorafenib might be suitable not only for patients with HCC with activated IGF1R but also for a subset of patients with HCC with ALK activation as well as for patients showing both IGF1R and ALK activation.
It has been shown that IGF1R activation leads to both PI3/AKT and RAS/RAF/ERK activation. (8) However, we found that knockdown of IGF1R or ceritinib inhibits only the activation of AKT but not ERK in HCC cells (Fig. 2A) . The failure to inhibit ERK activity may explain why knockdown of IGF1R or the use of ceritinib alone has a modest effect on HCC cell growth and survival. On the other hand, sorafenib treatment is sufficient to effectively inhibit ERK activity but not AKT activity in HCC cells (Fig. 1A) . Therefore, the combined use of sorafenib and ceritinib leads to inhibition of both ERK and AKT activities, which results in profound inhibition of HCC cell growth and ultimately cell death (Fig. 7) . The mechanisms by which IGF1R inhibition fails to abrogate ERK activity in HCC cells remain unclear. It has been shown that A12, a monoclonal antibody against IGF1R, failed to inhibit ERK in leukemic cells treated with interleukin-3. (38) Therefore, it is possible that ERK can be activated by other upstream factors, such as interleukin-3, and that IGF1R is not a major regulator of ERK activation in HCC cells.
In conclusion, our study shows that IGF1R inhibition effectively sensitizes HCC cells to sorafenib treatment by inhibiting AKT activity. The combined inhibition of IGF1R using ceritinib and sorafenib may offer an improved strategy to treat HCC. As ceritinib is already FDA approved, a clinical trial using combination treatment with sorafenib is warranted. A number of IGF1R inhibitors have been developed and are being studied in clinical trials for multiple types of solid tumors. A combination of one of these inhibitors plus sorafenib might provide a new direction in HCC therapy, especially in patients with activated IGF1R.
